Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W2RM | ISIN: US00847X1046 | Ticker-Symbol: 8AP
Tradegate
31.03.25
14:54 Uhr
28,200 Euro
+0,200
+0,71 %
1-Jahres-Chart
AGIOS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AGIOS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
27,20027,40021:45
27,20027,40021:45

Aktuelle News zur AGIOS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.03.Agios Pharmaceuticals, Inc.: Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer68CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...
► Artikel lesen
05.03.AGIOS PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
04.03.Kaufmännische Leiterin von Agios Pharmaceuticals verkauft Aktien im Wert von 59.742 US-Dollar2
AGIOS Aktie jetzt für 0€ handeln
04.03.Agios Pharmaceuticals CEO verkauft Aktien im Wert von 460.135 US-Dollar1
24.02.H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating3
19.02.Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript2
14.02.Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues2
13.02.Agios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 20255
13.02.Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years1
13.02.AGIOS PHARMACEUTICALS, INC. - 10-K, Annual Report-
13.02.Agios Pharmaceuticals reports Q4 results1
13.02.Agios Pharmaceuticals, Inc.: Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint116- ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused - - Safety Results Consistent with Safety Profile for...
► Artikel lesen
13.02.Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights147- Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union...
► Artikel lesen
13.02.AGIOS PHARMACEUTICALS, INC. - 8-K, Current Report-
12.02.Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb6
12.02.Agios Pharmaceuticals Q4 2024 Earnings Preview2
20.01.Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0%4
13.01.Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential2
13.01.AGIOS PHARMACEUTICALS, INC. - 8-K, Current Report-
09.01.FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia25
Seite:  Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1